

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

Trent M. WOODRUFF et al.

Application No.: 10/594,358

Filed: March 21, 2005 (Int'l)

For: TREATMENT OF NEUROLOGICAL  
CONDITIONS USING COMPLEMENT C5a  
RECEPTOR MODULATORS

Confirmation No.: 4642

Art Unit: 1654

Examiner: Ronald T. Niebauer

**RESPONSE TO RESTRICTION AND/OR ELECTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to an Office action herein, mailed 17 March 2008, which is a requirement for a species election, time for response to which was set to expire 17 April 2008. A petition for an extension of time of two (2) months until 17 June 2008 is attached hereto, along with the required fee. Applicants make the following election:

1. Inhibitor Compound: Applicants elect PMX53, illustrated in Figure 1 wherein A is NH-acyl, B is benzyl, C is the sidechain of L-proline, D is the sidechain of

2. The disease elected is Parkinson's disease.
3. The other agent is infliximab.

Applicants understand that should the elected species be found allowable and lead to the allowance of a generic claim, other species will be examined as well.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 229752004900.

Dated: June 17, 2008

By: \_\_\_\_\_ / Kate H. Murashige /  
Kate H. Murashige  
Registration No.: 29,959  
**MORRISON & FOERSTER LLP**  
12531 High Bluff Drive, Suite 100  
San Diego, California 92130-2040  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125